Effect of TAK-147, a novel AChE inhibitor, on cerebral energy metabolism

[1]  M. Victor.  Memory loss with lesions of hippocampal formation , 1996 .

[2]  R. Dejong.  Memory loss due to hippocampal lesions , 1996 .

[3]  M. Miyamoto,et al.  Central Cholinergic Agents. Part 6. Synthesis and Evaluation of 3‐(1‐( Phenylmethyl)‐4‐piperidinyl)‐1‐(2,3,4,5‐tetrahydro‐1H‐1‐benzazepin‐8‐ yl)‐1‐propanones and Their Analogues as Central Selective Acetylcholinesterase Inhibitors. , 1994 .

[4]  R. Kauppinen,et al.  Nuclear magnetic resonance spectroscopy studies of the brain , 1994, Progress in Neurobiology.

[5]  M. Miyamoto,et al.  Central cholinergic agents. 6. Synthesis and evaluation of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepi n-8-yl)-1-propanones and their analogs as central selective acetylcholinesterase inhibitors. , 1994, Journal of medicinal chemistry.

[6]  J. Edeline,et al.  Basal forebrain stimulation facilitates tone-evoked responses in the auditory cortex of awake rat , 1993, Neuroscience.

[7]  Y. Lamour,et al.  Tetrahydroaminoacridine and Physostigmine Increase Cerebral Glucose Utilization in Specific Cortical and Subcortical Regions in the Rat , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  J. Mcculloch,et al.  Abnormalities in rCBF and computed tomography in patients with Alzheimer's disease and in controls. , 1993, The British journal of radiology.

[9]  R F Woolson,et al.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. , 1992, The New England journal of medicine.

[10]  Klaus P. Ebmeier,et al.  Cerebral blood flow in Alzheimer's disease imaged by Positron Emission Tomography: the effects of physostigmine infusion , 1992 .

[11]  B. Sahakian,et al.  Tacrine in Alzheimer's disease , 1991, The Lancet.

[12]  B. J. Shepstone,et al.  Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease , 1990, The Lancet.

[13]  N. Cutler,et al.  Clinical Safety, Tolerance, and Plasma Levels of the Oral Anticholinesterase 1,2,3,4‐Tetrahydro‐9‐aminoacridin‐1‐oL‐maleate (HP 029) in Alzheimer's Disease: Preliminary Findings , 1990, Journal of clinical pharmacology.

[14]  Klaus P. Ebmeier,et al.  Dementia: the role of neurotransmitter deficits , 1990 .

[15]  F. Frost.  Current Research in Alzheimer Therapy , 1989 .

[16]  A. Gjedde,et al.  Does deoxyglucose uptake in the brain reflect energy metabolism? , 1987, Biochemical pharmacology.

[17]  D L Schacter,et al.  Neurochemical dissociation of memory systems , 1987, Neurology.

[18]  J. Hawthorne,et al.  Cellular and molecular basis of cholinergic function , 1987 .

[19]  A. Kling,et al.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.

[20]  J. Krieglstein,et al.  The effects of tifluadom and ketazocine on behaviour, dopamine turnover in the basal ganglia and local cerebral glucose utilization of rats , 1986, Brain Research.

[21]  J. Haxby,et al.  Positron emission tomography in Alzheimer's disease , 1986, Neurology.

[22]  J. Krieglstein,et al.  Effects of the indirect dopaminomimetic diethylpemoline on local cerebral glucose utilization and local cerebral blood flow in the conscious rat. , 1986, European journal of pharmacology.

[23]  B. Winblad,et al.  Transmitter deficits in Alzheimer's disease , 1985, Neurochemistry International.

[24]  L. Sokoloff,et al.  Influence of γ-Hydroxybutyrate on the Relationship between Local Cerebral Glucose Utilization and Local Cerebral Blood Flow in the Rat Brain , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  Robert P. Friedland,et al.  Alzheimer's disease: Anterior-posterior and lateral hemispheric alterations in cortical glucose utilization , 1985, Neuroscience Letters.

[26]  P. Francis,et al.  Neurotransmitter and Metabolic Dysfunction in Alzheimer’s Dementia: Relationship to Histopathological Features , 1985 .

[27]  K. Davis,et al.  Oral physostigmine treatment of patients with Alzheimer's disease. , 1985, The American journal of psychiatry.

[28]  Luigi Mansi,et al.  Cortical abnormalities in Alzheimer's disease , 1984, Annals of neurology.

[29]  Carolyn B. Smith.  Aging and changes in cerebral energy metabolism , 1984, Trends in Neurosciences.

[30]  E. London,et al.  Aging and cholinergic system: a 2-deoxyglucose study in the rat brain. , 1984, Monographs in neural sciences.

[31]  D. Benson,et al.  The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. , 1983, Archives of neurology.

[32]  R. Bryan,et al.  Cerebral glucose utilization in awake unstressed rats. , 1983, The American journal of physiology.

[33]  L. Sokoloff,et al.  Local Cerebral Glucose Utilization in Hypothermic and Hyperthermic Rats , 1982, Journal of neurochemistry.

[34]  Michael E. Phelps,et al.  Effects of Human Aging on Patterns of Local Cerebral Glucose Utilization Determined by the [18F] Fluorodeoxyglucose Method , 1982, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  M. Marcus,et al.  Effect of acetylcholine and vasoactive intestinal peptide on cerebral blood flow. , 1980, The American journal of physiology.

[36]  L. Sokoloff,et al.  Effects of ageing on local rates of cerebral glucose utilization in the rat. , 1980, Brain : a journal of neurology.

[37]  M. Reivich,et al.  The effect of scopolamine on local glucose metabolism in rat brain , 1979, Brain Research.

[38]  J. Marshall,et al.  Movement disorders of aged rats: reversal by dopamine receptor stimulation. , 1979, Science.

[39]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.

[40]  C. Gryfe.  Mechanical Concepts in Cardiovascular and Pulmonary Physiology. , 1978 .

[41]  L. Sokoloff,et al.  RELATION BETWEEN PHYSIOLOGICAL FUNCTION AND ENERGY METABOLISM IN THE CENTRAL NERVOUS SYSTEM , 1977, Journal of neurochemistry.

[42]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[43]  L. Edvinsson,et al.  Possibilities for a cholinergic action on smooth musculature and on sympathetic axons in brain vessels mediated by muscarinic and nicotinic receptors. , 1977, The Journal of pharmacology and experimental therapeutics.

[44]  B. Siesjö,et al.  Glucose consumption in rat cerbral cortex in normoxia, hypoxia and hypercapnia. , 1976, Acta physiologica Scandinavica.

[45]  E. Miller.  Impaired recall and the memory disturbance in presenile dementia. , 1975, The British journal of social and clinical psychology.

[46]  W. Werner,et al.  Über die Eigenschaften eines neuen Chromogens für die Blutzuckerbestimmung nach der GOD/POD-Methode , 1970 .

[47]  H. Itabashi,et al.  Memory loss due to hippocampal lesions. Report of a case. , 1969, Archives of neurology.

[48]  M. Victor,et al.  [Memory loss with lesions of hippocampal formation. Report of a case with some remarks on the anatomical basis of memory]. , 1961, Archives of neurology.